Atsufumi Kawabata, Ph.D.

Professor

 

ΰ–Ύ: To Lab Homepage in Englishΰ–Ύ: To Lab Homepage in Japanese

ΰ–Ύ: ak-shadow

Address

Division of Pharmacology & Pathophysiology

Department of Pharmacy, Faculty of Pharmacy

Kindai University

3-4-1 Kowakae, Higashi-Osaka 577-8502

Japan

 

Tel. 06-4307-3631

Fax. 06-6730-1394

Email: kawabata@-----------------

    When you email me, please type ephar.kindai.ac.jpf after ekawabata@f.

 

CV

ΰ–Ύ: kawabata2008

2020-the present Head of Department of Pharmacy, Faculty of Pharmacy, Kindai University

2008-2012, 2016-2020 Head of Kindai University Graduate School of Pharmacy

2007 (up to the present) Professor at Division of Pharmacology & Pathophysiology, Department of Pharmacy, School of Pharmacy, Kindai University

2006  Professor at Division of Physiology & Pathophysiology, Department of Pharmacy, School of Pharmacy, Kindai University

2005  Professor at Division of Physiology & Pathophysiology, School of Pharmaceutical Sciences, Kindai University

2003  Associate Professor at Division of Physiology & Pathophysiology, School of Pharmaceutical Sciences, Kindai University

2001  Associate Professor at Division of Pathophysiology & Therapeutics, School of Pharmaceutical Sciences, Kindai University

1998 Lecturer at Division of Pathophysiology & Therapeutics, School of Pharmaceutical Sciences, Kindai University

1996-1997      Visiting Scientist at Department of Pharmacology & Therapeutics, Faculty of Medicine, University of Calgary

1994  Ph.D. (Kindai University)

1985  Assistant at Division of Pharmacology, School of Pharmaceutical Sciences, Kindai University

1985  M.Sci. (Kindai University)

1983  B.Sci. (Kindai University)

1960  Born in Osaka.

 

Kinyaku26th Alumni

 

Research Project

 

1. Study on T-type calcium channels

 

We found that H2S, the third gasotransmitter, targets Cav3.2 T-type calcium channels, playing various the roles in the mammalian body including processing of pain signals, neuritogenesis and modulation of inflammatory responses. We now focus on the development of novel medicines targeting Cav3.2, in collaboration with laboratories in other universities and pharmaceutical companies.

 

Free Review Articles:

Sekiguchi and Kawabata, J Pharmacol Sci 122, 244-250 (2013)       https://www.jstage.jst.go.jp/article/jphs/122/4/122_13R05CP/_article

 

Schemes shown in articles:

Tomita, S., Sekiguchi, F., Deguchi, T., Miyazaki, T., Ikeda, Y., Tsubota, M., Yoshida, S., Nguyen, H.D., Okada, T., Toyooka, N., Kawabata, A., Toxicology 413, 33-39 (2019) https://www.ncbi.nlm.nih.gov/pubmed/30552955

 

 

2. Study on proteinase-activated receptors (PARs)

Proteinase-activated receptors belong to a novel family of G protein-coupled, seven trans-membrane domain receptors that consists of four members, PARs 1, 2, 3 and 4. We have been investigating the physiological and/or pathophysiological roles for PARs as novel targets for development of drugs. We have reported the roles for PARs in inflammation and in modulation of duodenal smooth muscle tone and of salivary and pancreatic exocrine secretion. In this project, we have a lot of collaboration with foreign universities, pharmaceutical companies and some laboratories in our own university and others.

 

Free Review Articles:

Kawabata, Matsunami, Sekiguchi, Br J Pharmacol Suppl 1, S230-S240 (2008)   http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2268065/

 

 

 

3. Study on HMGB1

We found that high mobility group box 1 (HMGB1), one of damage associated molecular patterns (DAMPs), participates in pain processing.

 

Schemes shown in articles:

u   Tsujita, Tsubota, Hayashi, Saeki, Sekiguchi, Kawabata, J Neuroimmune Pharmacol, in press (2018)   https://www.ncbi.nlm.nih.gov/pubmed/29196860

™Prevention of HMGB1-induced allodynia by thrombomodulin alfa is dependent on thrombin.

Fig5

 

u   Hayashi, Tsujita, Tsubota, Saeki, Sekiguchi, Honda, Kawabata, Biochem Biophys Res Commun 495, 634-638 (2018) (2018)   https://www.ncbi.nlm.nih.gov/pubmed/29146186

™Prevention of HMGB1-induced allodynia by thrombomodulin alfa requires a minimum structure of D1-D2.

Fig4

u  Sekiguchi, Domoto, Nakashima, Yamasoba, Yamanishi, Tsubota, Wake, Nishibori, Kawabata, Neuropharmacology 141, 201-213 (2018) https://www.ncbi.nlm.nih.gov/pubmed/30179591

™Paclitaxel-induced peripheral neuropathy involves macrophage-derived HMGB1.

 

4. Study on pain modulation

Another project is about pain. We are now studying the modulation mechanisms of pain information in the brain, spinal cord and periphery. We wish to develop novel analgesics that can suppress intractable pain like neuropathic pain. We are now studying pain modulation by prostaglandin E2 and HMGB1 in addition to the above mentioned H2S, T-type calcium channels and PARs. Our study aims at developing novel analgesics for treatment of persistent pain including neuropathic pain.

 

Free Review Articles:

Kawabata, Biol Pharm Bull 34, 1170-1173 (2011)   https://www.jstage.jst.go.jp/article/bpb/34/8/34_8_1170/_article

PGE2-Pain-scheme-BPB

 

 

 

 

 

Recent publications (1998 -)

           (*Corresponding author)

1.     Iwane, S., Nemoto, W. (co-first author), Miyamoto, T., Hayashi, T., Tanaka, M., Uchitani, K., Muranaka, T., Fujitani, M., Koizumi, Y., Hirata, A., Tsubota, M., Sekiguchi, F., Tan-No, K., Kawabata, A.* (2024) Clinical and preclinical evidence that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prevent diabetic peripheral neuropathy. Sci. Rep., 14, 1039. PubMed

2.     Kasanami, Y., Yamamoto, T., Miyamoto, T., Matzno, S., Sakakibara, M., Iwaki, M., Kawabata, A.* (2023) Characterization of potentially inappropriate medications that need special attention in the elderly with dementia by analyzing pharmacy claims data. Biol. Pharm. Bull., 46, 1699-1705. PubMed

3.     Tomita, S., Sekiguchi, F., Tsubota, M., Kawabata, A.* (2023) Dietary zinc deficiency induces Cav3.2-dependent nociceptive hypersensitivity in mice. Biol. Pharm. Bull., 46, 1343-1346. PubMed

4.     Tomita, S., Sekiguchi, F., Naoe, K., Shikimi, S., Kasanami, Y., Ohigashi, M., Tsubota, M., Kawabata, A.* (2023) Cav3.2-dependent hyperalgesia/allodynia following intrathecal and intraplantar zinc chelator administration in rodents. J. Pharmacol. Sci., 152, 86-89. PubMed

5.     Sekiguchi, F., Koike, N. (co-first author), Shimada, Y. (co-first author), Sugimoto, K., Masuda, H., Nakamura, T., Yamaguchi, H., Tababe, G., Marumoto, S., Kasanami, Y., Tsubota, M., Ohkubo, T., Yoshida, S., Kawabata, A.* (2023) A hydrolysate of poly-trans-[(2-carboxyethyl)germasesquioxane] (Ge-132) suppresses Cav3.2-dependent pain by sequestering exogenous and endogenous sulfide. Redox Biol., 59, 102579. PubMed Outstanding paper

6.     Maeda, T., Sekiguchi, F. (co-first author), Mitani, K., Yamagata, R., Tsubota, M., Yoshida, S., Kawabata, A.* (2023) Opioid modulation of T-type Ca2+ channel-dependent neuritogenesis/neurite outgrowth through the prostaglandin E2/EP4 receptor/protein kinase A pathway in mouse dorsal root ganglion neurons. Biochem. Biophys. Res. Commun., 639, 142-149. PubMed

7.     Kasanami, Y., Ishikawa, C., Kino, T., Chonan, M., Toyooka, N.*, Takashima, Y., Iba, Y., Sekiguchi, F., Tsubota, M., Ohkubo, T., Yoshida, S., Kawase, A., Okada, T.*, Kawabata, A.* (2022) Discovery of Pimozide Derivatives as Novel T-type Calcium Channel Inhibitors with Little Binding Affinity to Dopamine D2 Receptors for Treatment of Somatic and Visceral Pain. Eur. J. Med. Chem., 243, 114716. PubMed

8.     Miyamoto, T., Domoto, R. (co-first author), Sekiguchi, F., Kawaguchi, R., Nishimura, R., Matsuno, M., Tsubota, M., Fujitani, M., Hatanaka, S., Koizumi, Y., Wang, D., Nishibori, M., Kawabata, A.* (2022) Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Evidence from clinical and preclinical studies. J. Pharmacol. Sci., 148 (3), 315-325. PubMed

9.     Domoto, R., Sekiguchi, F. (co-first author), Kamaguchi, R., Iemura, M., Yamanishi, H., Tsubota, M., Wang, D., Nishibori, M., Kawabata, A.* (2022) Role of neuron-derived ATP in paclitaxel-induced HMGB1 release from macrophages and peripheral neuropathy. J. Pharmacol. Sci., 148 (1), 156-161. PubMed

10. Ieda, S., Miyamoto, T. (co-first author), Hosomi, K., Takegami, M., Kawabata, A.* (2022) Identification of remaining life expectancy less than two weeks by CRP/albumin ratio, prognostic nutritional index, fibrosis-4 index and albumin-bilirubin score in terminal cancer patients. J. Palliat. Med., 25 (4), 570-576. PubMed

11. Hiramoto, S., Asano, H., Miyamoto, T., Takegami, M., Kawabata, A.* (2021) Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan. PLoS One, 16 (12), e0261473. PubMed

12. Tsubota, M., Miyazaki, T., Ikeda, Y., Hayashi, Y., Aokiba, Y., Tomita, S., Sekiguchi, F., Wang, D., Nishibori, M., Kawabata, A.* (2021) Caspase-dependent HMGB1 release from macrophages participates in peripheral neuropathy caused by bortezomib, a proteasome-inhibiting chemotherapeutic agent, in mice. Cells, 10, 2550. PubMed

13. Hayashi, T., Miyamoto, T., Nagai, N., Kawabata, A.* (2021) Development of diabetes mellitus following hormone therapy in prostate cancer patients is associated with early progression to castration resistance. Sci. Rep., 11, 17157. PubMed

14. Domoto, R., Sekiguchi, F. (co-first author), Tsubota, M. (co-first author), Kawabata, A.* (2021) Macrophage as a peripheral pain regulator. Cells, 10, 1881. (Review) PubMed

15. Sekiguchi, F., Kawabata, A.* (2021) Clinical therapy targeting proteinase-activated receptors. Clin. Neurosci. 39, 684-686. (Review)

16. Tsubota, M., Kawabata, A.* (2021) Physiological and pharmacological functions of proteinase-activated receptors. Clin. Neurosci. 39, 521-523. (Review)

17. Kawabata, A.* (2021) Subtypes of proteinase-activated receptors. Clin. Neurosci. 39, 390-393. (Review)

18. Miyamoto, T., Hiramoto, S. (co-first author), Kanto, Y., Tsubota, M., Fujitani, M., Furuyama, H., Hatanaka, S., Sekiguchi, F., Koizumi, Y., Kawabata, A.* (2021) Estrogen decline is a risk factor for paclitaxel-induced peripheral neuropathy: clinical evidence supported by a preclinical study. J. Pharmacol. Sci., 146, 49-57. PubMed

19. Tsubota, M., Matsui, K. (co-first author), Fukushi, S., Okazaki, K., Sekiguchi, F., Kawabata, A.* (2021) Effects of bepridil and pimozide, existing medicines capable of blocking T-type Ca2+ channels, on visceral pain in mice. Biol. Pharm. Bull., 44, 461-464. PubMed

20. Sekiguchi, F., Kawabata, A.* (2020) Role of HMGB1 in chemotherapy-induced peripheral neuropathy. Int. J. Mol. Sci., 22 (1), 367. (Review) PubMed

21. Tsujita, R., Tsubota, M. (co-first author), Sekiguchi, F., Kawabata, A.* (2021) Role of high mobility group box 1 and its modulation by thrombomodulin/thrombin axis in neuropathic and inflammatory pain. Br. J. Pharmacol., 178, 798-812. (Review)  PubMed

22. Tomita, S., Sekiguchi, F. (co-first author), Kasanami, Y., Naoe, K., Tsubota, M., Wake, H., Nishibori, M., Kawabata, A.* (2020) Cav3.2 overexpression in L4 dorsal root ganglion neurons after L5 spinal nerve cutting involves Egr-1, USP5 and HMGB1 in rats: an emerging signaling pathway for neuropathic pain. Eur. J. Pharmacol., 888, 173587. PubMed

23. Tsubota, M., Matsui, K., Nakano, M., Kajitani, R., Ishii, Y., Tomochika, K., Nishikawa, Y., Fukushi, S., Yamagata, A., Sekiguchi, F., Okada, T., Toyooka, N., Kawabata, A.* (2020) Essential role of Cav3.2 T-type calcium channels in butyrate-induced colonic pain and nociceptor hypersensitivity in mice. Eur. J. Pharmacol., 887, 173576. PubMed

24. Miyamoto, T.*, Fujitani, M., Hatanaka, S., Koizumi, Y., Kawabata, A. (2020) Use of transdermal fentanyl and elevated gamma-glutamyl transpeptidase levels are associated with increased total daily dose of opioid. Jpn J Pharm Palliat Care Sci, in press.

25. Hiramoto, S., Tsubota, M. (co-first author), Yamaguchi, K., Okazaki, K., Sakaegi, A., Toriyama, Y., Tanaka, J., Sekiguchi, F., Ishikura, H., Wake, H., Nishibori, M., Nguyen, H.D., Okada, T., Toyooka, N., Kawabata,A.* (2020) Cystitis-related bladder pain involves ATP-dependent HMGB1 release from macrophages and its downstream H2S/Cav3.2 signaling in mice. Cells, 9, 1748. PubMed

26. Matsui, K., Mukai, Y., Sakakura, K., Wada, K., Nakamura, T., Kawabata, A., Terakawa, N., Hayakawa, N., Kusano, K., Hosomi, K., Yokoyama, S., Takada, M.* (2020) Relationship between serum bepridil concentration and corrected QT interval. Int. J. Clin. Pharmacol. Ther., 59 (1), 63-70. PubMed 

27. Hayashi, T., Kawaguchi, H., Eifuku, T., Matsuoka, H., Kawabata, A., Nagai, N.* (2020) Changes in percutaneous absorption of fentanyl patches in rats treated with a sebum-like secretion. Chem. Pharm. Bull., 68 (9), 879-884. PubMed

28. Okamoto, H., Yoshikawa, T., Takeuchi, K., Deguchi, S., Hatakenaka, Y., Matsuoka, H., Kawabata, A., Nagai, N.* (2020) A combination of cryopreservation and kneading maintains the usability of Mohs past. Chem. Pharm. Bull., 68 (6), 516-519. PubMed

29. Irie, Y., Tsubota, M. (co-first author), Maeda, M., Hiramoto, S., Sekiguchi, F., Ishikura, H., Wake, H., Nishibori, M., Kawabata, A.* (2020) HMGB1 and its membrane receptors as therapeutic targets in an intravesical substance P-induced bladder pain syndrome mouse model. J. Pharmacol. Sci., 143 (2), 112-116. PubMed

30. Matsui, K., Terada, Y., Tsubota, M., Sekiguchi, F., Kawabata, A.* (2020) Tacrolimus, a calcineurin inhibitor, promotes capsaicin-induced colonic pain in mice. J. Pharmacol. Sci., 143 (1), 60-63. PubMed

31. Hayashi, T., Takashina, Y., Kawaguchi, H., Eifuku, T., Matsuoka, H., Kawabata, A., Nagai, N.* (2019) Evaluation of transdermal penetration in fentanyl tape using Franz diffusion cell: changes in drug release and skin permeation under the hyperthermia. Jpn. J. Pharmaceut. Health Care Sci., 45, 416-422.

32. Tsubota, M., Fukuda, R., Hayashi, Y., Miyazaki, T., Ueda, S., Yamashita, R., Koike, N., Sekiguchi, F., Wake, H., Wakatsuki, S., Ujiie, Y., Araki, T., Nishibori, M., Kawabata, A.* (2019) Role of non-macrophage cell-derived HMGB1 in oxaliplatin-induced peripheral neuropathy and its prevention by the thrombin/thrombomodulin system in rodents: negative impact of anticoagulants. J. Neuroinflammation., 16 (1), 199. PubMed

33. Matsui, K., Tsubota, M. (co-first author), Fukushi, S., Koike, N., Masuda, H., Kasanami, Y., Miyazaki, T., Sekiguchi, F., Ohkubo, T., Yoshida, S., Mukai, Y., Oita, A., Takada, M., Kawabata, A.* (2019) Genetic deletion of Cav3.2 T-type calcium channels abolishes H2S-dependent somatic and visceral pain signaling in C57BL/6 mice. J. Pharmacol. Sci., 140, 310-312. PubMed 

34. Kawabata, A.*, Tsubota, M., Sekiguchi, F., Tsujita, R. (2019) HMGB1 as a target for prevention of chemotherapy-induced peripheral neuropathy. Nihon Yakurigaku Zasshi, 154, 236-240. (Review) PubMed

35. Sekiguchi, F.*, Kawabata, A. (2019) Role of Cav3.2 T-type Ca2+ channels in prostate cancer cells. Nihon Yakurigaku Zasshi, 154, 97-102. (Review) PubMed

36. Tsubota, M.*, Kawabata, A. (2019) Regulation of Cav3.2-mediated pain signals by hydrogen sulfide. Nihon Yakurigaku Zasshi, 154, 128-132. (Review) PubMed

37. Nguyen, H.D.*, Okada, T., Sekiguchi, F., Tsubota, M., Nishikawa, H., Kawabata, A., Toyooka, N. (2019) Prenylflavanones as novel T-type calcium channel blockers useful for pain therapy. Nat. Prod. Commun., in press. (Review)  Journal HP

38. Tsubota, M., Uebo, K., Miki, K., Sekiguchi, F., Ishigami, A., Kawabata, A.* (2019) Dietary ascorbic acid restriction in GNL/SMP30-knockout mice unveils the role of ascorbic acid in regulation of somatic and visceral pain sensitivity. Biochem. Biophys. Res. Commun., 511, 705-710. PubMed

39. Matsuda, S., Nishikawa, H. (co-first author), Fukatsu, A., Kurokawa, Y., Tsubota, M., Sekiguchi, F., Tokuyama, S., Kawabata, A.* (2019) NNC 55-0396, a T-type calcium channel blocker, protects against the brain injury induced by middle cerebral artery occlusion and reperfusion in mice. J. Pharmacol. Sci., 140, 193-196. PubMed

40. Tomita, S., Sekiguchi, F., Deguchi, T., Miyazaki, T., Ikeda, Y., Tsubota, M., Yoshida, S., Nguyen, H.D., Okada, T., Toyooka, N., Kawabata, A.* (2019) Critical role of Cav3.2 T-type calcium channels in the peripheral neuropathy induced by bortezomib, a proteasome-inhibiting chemotherapeutic agent, in mice. Toxicology, 413, 33-39. PubMed

41. Tsubota, M., Kawabata, A.* (2019) Role of macrophage-derived HMGB1 as an algogenic molecule/therapeutic target in visceral pain. Pain Res., 34, 24-30. (Review)

42. Koizumi, Y.*, Ishiwata, S., Inoue, T., Takada, M., Kawabata, A., Kotake, T. (2019) Investigation of the levels of ifosfamide vaporized from powder and solution. Jpn. J. Occup. Med. Traumatol. 67, 95-99.

43. Miyamoto, T.*, Fukuyama, H., Hatanaka, S., Fujitani, M., Koizumi, Y., Kawabata, A. (2019) The C-reactive protein/albumin ratio is useful for predicting short-term survival in cancer and non-cancer patients. J. Palliat. Med., 22, 532-537. PubMed

44. Sekiguchi, F., Domoto, R. (co-first author), Nakashima, K., Yamasoba, D., Yamanishi, H., Tsubota, M., Wake, H., Nishibori, M., Kawabata, A.* (2018) Paclitaxel-induced HMGB1 release from macrophages and its implication for peripheral neuropathy in mice: evidence for a neuroimmune cross talk. Neuropharmacology, 141, 201-213. PubMed

45. Nguyen, H.D., Okada, T., Kitamura, S., Yamaoka, S., Horaguchi, Y., Kasanami, Y., Sekiguchi, F., Tsubota, M., Yoshida, S., Nishikawa, H. Kawabata, A.*, Toyooka, N.* (2018) Design and synthesis of novel anti-hyperalgesic agents based on 6-prenylnaringenin as the T-type calcium channel blockers. Bioorg. Med. Chem., 26, 4410-4427. PubMed

46. Sekiguchi, F., Fujita, T., Deguchi, T., Yamaoka, S., Tomochika, K., Tsubota, M., Ono, S., Horaguchi, Y., Ichii, M., Ichikawa, M., Ueno, Y., Koike, N., Tanino, T., Nguyen, H.D., Okada, T., Nishikawa, H., Yoshida, S., Ohkubo, T., Toyooka, N., Murata, K., Matsuda, H., Kawabata, A.* (2018) Blockade of T-type calcium channels by 6-prenylnaringenin, a hop component, alleviates neuropathic and visceral pain in mice. Neuropharmacology, 138, 232-244. PubMed

47. Sekiguchi, F., Tsubota, M., Kawabata, A.* (2018) Involvement of voltage-gated calcium channels in inflammation and inflammatory pain. Biol. Pharm. Bull., 41, 1127-1134. PubMed  (Review)

48. Tsubota, M., Okawa, Y., Irie, Y., Maeda, M., Ozaki, T., Sekiguchi, F., Ishikura, H., Kawabata, A.* (2018) Involvement of the cystathionine-ƒΑ-lyase/Cav3.2 pathway in substance P-induced bladder pain in the mouse, a model for nonulcerative bladder pain syndrome. Neuropharmacology, 133, 254-263. PubMed

49. Tsubota, M., Ozaki, T. (co-first author), Hayashi, Y., Okawa, Y., Fujimura, A., Sekiguchi, F., Nishikawa, H., Kawabata, A.* (2018) Prostanoid-dependent bladder pain caused by proteinase-activated receptor-2 activation in mice: Involvement of TRPV1 and T-type Ca2+ channels. J. Pharmacol. Sci., 136, 46-49. PubMed

50. Tsujita, R., Tsubota, M. (co-first author), Hayashi, Y. (co-first author), Saeki, H., Sekiguchi, F., Kawabata, A.* (2018) Role of thrombin in soluble thrombomodulin-induced suppression of peripheral HMGB1-mediated allodynia in mice. J. Neuroimmune Pharmacol., 13, 179-188. PubMed

51. Hayashi, Y., Tsujita, R. (co-first author), Tsubota, M. (co-first author), Saeki, H., Sekiguchi, F., Honda, G., Kawabata, A.* (2018) Human soluble thrombomodulin-induced blockade of peripheral HMGB1-dependent allodynia in mice requires both the lectin-like and EGF-like domains. Biochem. Biophys. Res. Commun., 495, 634-638.  PubMed

52. Ozaki, T., Matsuoka, J., Tsubota, M., Tomita, S., Sekiguchi, F., Minami, T., Kawabata, A.* (2018) Zinc deficiency promotes cystitis-related bladder pain by enhancing function and expression of Cav3.2 in mice. Toxicology, 393, 102-112. PubMed

53. Ozaki, T., Tsubota, M., Sekiguchi, F., Kawabata, A.* (2018) Involvement of NF-ƒΘB in the upregulation of cystathionine-ƒΑ-lyase, a hydrogen sulfide-forming enzyme, and bladder pain accompanying cystitis in mice. Clin. Exp. Pharmacol. Physiol., 45, 355-361. PubMed

54. Irie, Y., Tsubota, M. (co-first author), Ishikura, H., Sekiguchi, F., Terada, Y., Tsujiuchi, T., Liu, K., Nishibori, M., Kawabata, A.* (2017) Macrophage-derived HMGB1 as a pain mediator in the early stage of acute pancreatitis in mice: targeting RAGE and CXCL12/CXCR4 axis. J. Neuroimmune Pharmacol., 12, 693-707. PubMed

55. Sekiguchi, F., Kawabata, A.* (2017) Functional regulation of ion channels by H2S and its phathological impact. Sulphuric acid and industry, 80 (5), 61-70. (Review)

56. Tsubota, M., Miyamoto, T., Hiruma, S., Saeki, H., Miyazaki, T., Sekiguchi, F., Funakami, Y., Kawabata, A.* (2017) Repeated cold stress reduces cyclophosphamide-induced cystitis/bladder pain and macrophage activity in mice. Pharmacology, 99, 286-290. PubMed

57. Tsubota, M., Kawabata, A.* (2017) Therapeutic application of thrombomodulin alfa for visceral pain. Ulcer Res. (Kaiyou), 44, 48-53. (Review)

58. Fukami, K., Asano, E., Ueda, M., Sekiguchi, F., Yoshida, S., Kawabata, A.* (2017) High glucose induces N-linked glycosylation-mediated functional upregulation and overexpression of Cav3.2 T-type calcium channels in neuroendocrine-like differentiated human prostate cancer cells. J. Pharmacol. Sci., 133, 57-60. PubMed

59. Miyamoto, T., Funakami, Y., Kawashita, E., Tomita, S., Nomura, A., Sugimoto, N., Saeki, H., Tsubota, M., Ichida, S., Kawabata, A.* (2017) Enhanced hyperthermic responses to lipopolysaccharide in mice exposed to repeated cold stress. Pharmacology, 99, 172-178. PubMed

60. Miyamoto, T., Funakami, Y., Kawashita, E., Nomura, A., Sugimoto, N., Saeki, H., Tsubota, M., Ichida, S., Kawabata, A.* (2017) Repeated cold stress enhances the acute restraint stress-induced hyperthermia in mice. Biol. Pharm. Bull., 40, 1-6. PubMed

61. Terada, Y., Tsubota, M., Sugo, H., Wakitani, K., Sekiguchi, F., Wada, K., Takada, M., Oita, A., Kawabata, A.* (2017) Tacrolimus triggers TRPV1-dependent relapse of pancreatitis-related pain in mice. Pharmacology, 99, 281-285. PubMed

62. Terada, Y., Wada, K.*, Matsuda, S., Kuwahara, T., Kawabata, A., Takada, M., Watanabe, T., Nakajima, S., Sato, T., Seguchi, O., Yanase, M., Fukushima, N., Nakatani, T. (2017) Circadian pharmacokinetics and limited sampling strategy of everolimus in heat transplant patients. Int. J. Clin. Pharmacol. Ther., 55 (1), 1-8. PubMed

63. Fukami, K., Sekiguchi, F., Kawabata, A.* (2016) Hydrogen sulfide and T-type Ca2+ channels in pain processing, neuronal differentiation and neuroendocrine secretion. Pharmacology, 99, 176-203. PubMed (Review)

64. Tsubota, M., Kawabata, A.* (2016) Nociceptors involved in pancreatitis-related pain and their importance as therapeutic targets. Tan to Sui, 37, 1535-1539. (Review)

65. Nishida, T., Tsubota, M. (co-first author), Kawaishi, Y., Yamanishi, H., Kamitani, N., Sekiguchi, F., Ishikura, H., Liu, K., Nishibori, M., Kawabata, A.* (2016) Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats. Toxicology, 365, 48-58. PubMed

66. Sekiguchi, F., Kawara, Y., Tsubota, M., Kawakami, E., Ozaki, T., Kawaishi, Y., Tomita, S., Kanaoka, D., Yoshida, S., Ohkubo, T., Kawabata, A.* (2016) Therapeutic potential of RQ-00311651, a novel T-type Ca2+ channel blocker, in distinct rodent models for neuropathic and visceral pain. Pain, 157, 1655-1665. PubMed 

67. Mitani, K., Sekiguchi, F., Maeda, T., Tanaka, Y., Kawabata, A.* (2016) The prostaglandin E2/EP4 receptor/cyclic AMP/T-type Ca2+ channel pathway mediates neuritogenesis in sensory neuron-like ND7/23 cells. J. Pharmacol. Sci., 130, 177-180. PubMed

68. Sekiguchi, F., Sekimoto, T., Ogura, A., Kawabata, A.* (2016) Endogenous hydrogen sulfide enhances cell proliferation of human gastric cancer AGS cells. Biol. Pharm. Bull., 39, 887-890. PubMed

69. Yamasoba, D., Tsubota, M., Domoto, R., Sekiguchi, F., Nishikawa, H., Liu, K., Nishibori, M., Ishikura, H., Yamamoto, T., Taga, A., Kawabata, A.* (2016) Peripheral HMGB1-induced hyperalgesia in mice: redox state-dependent distinct roles of RAGE and TLR4. J. Pharmacol. Sci., 130, 139-142. PubMed

70. Aoki, Y., Tsubota, M., Nishimoto, Y., Maeda, Y., Sekiguchi, F., Kawabata, A.* (2016) Selective sensitization of C-fiber nociceptors by hydrogen sulfide. J. Pharmacol. Sci., 130, 38-41. PubMed

71. Nagai, N., Yoshioka, C., Ito, Y.*, Funakami, Y., Nishikawa, F., Kawabata, A. (2015) Intravenous administration of cilostazol nanoparticles ameliorates acute ischemic stroke in a cerebral ischemia/reperfusion-induced injury model. Int. J. Mol. Sci., 16, 29329-29344. PubMed

72. Fukami, K., Sekiguchi, F., Yasukawa, M., Asano, E., Kasamatsu, R., Ueda, M., Yoshida, S., Kawabata, A.* (2015) Functional upregulation of the H2S/Cav3.2 channel pathway accelerates secretory function in neuroendocrine-differentiated human prostate cancer cells. Biochem. Pharmacol. 97, 300-309. PubMed

73. Terada, Y., Kawabata, A.* (2015) H2S and pain: a novel aspect for processing of somatic, visceral and neuropathic pain signals. In Chemistry, Biochemistry and Pharmacology of Hydrogen Sulfide, Handbook of Experimental Pharmacology, edited by Moore, P.K. and Whiteman, M., Springer, pp . (Book Chapter)

74. Fukami, K., Kawabata, A.* (2015) Hydrogen sulfide and neuronal differentiation: focus on Ca2+ channels. Nitric Oxide, 46, 50-54. PubMed (Review)

75. Murakami-Nakayama, M., Tsubota, M., Hiruma, S., Sekiguchi, F., Matsuyama, K., Kimura, T., Moriyama, M., Kawabata, A.* (2015) Polaprezinc attenuates cyclophosphamide-induced cystitis and related bladder pain in mice. J. Pharmacol. Sci., 127, 223-228. PubMed

76. Terada, Y., Fujimura, M., Nishimura, S., Tsubota, M., Sekiguchi, F., Kawabata, A.* (2015) Roles of Cav3.2 and TRPA1 channels targeted by hydrogen sulfide in pancreatic nociceptive processing in mice with or without acute pancreatitis. J. Neurosci. Res., 93, 361-369. PubMed

77. Takechi, M.*, Wada, T., Yagi, H., Masuko, T., Kawabata, A. (2015) Ouabain exerts cytoprotection by diminishing the intracellular K+ concentration increase caused by distinct stressful stimuli in human leukemic cells. J. Pharm. Pharmacol., 67, 126-132. PubMed

78. Maeda, Y., Sekiguchi, F., Yamanaka, R., Sugimoto, R., Yamasoba, D., Tomita, S., Nishikawa, H., Kawabata, A.* (2015) Mechanisms for proteinase-activated receptor 1-triggered prostaglandin E2 generation in mouse osteoblastic MC3T3-E1 cells. Biol. Chem., 396, 153-162. PubMed

79. Tsubota, M. *, Kawabata, A. (2014) Role of hydrogen sulfide, a gasotransmitter, in colonic pain and inflammation. Yakugaku Zasshi, 134, 1245-1252. PubMed (Review)

80. Sekiguchi, F., Miyamoto, Y., Kanaoka, D., Ide, H., Yoshida, S., Ohkubo, T., Kawabata, A.* (2014) Endogenous and exogenous hydrogen sulfide facilitates T-type calcium channel currents in Cav3.2-expressing HEK293 cells. Biochem. Biophys. Res. Commun., 445, 225-229. PubMed

81. Tanaka, J., Yamaguchi, K., Ishikura, H., Tsubota, M., Sekiguchi, F., Seki, Y., Tsujiuchi, T., Murai, A., Umemura, T., Kawabata, A.* (2014) Bladder pain relief by HMGB1 neutralization and soluble thrombomodulin in mice with cyclophosphamide-induced cystitis. Neuropharmacology, 79, 112-118. PubMed

82. Terada, Y., Fujimura, M., Nishimura, S., Tsubota, M., Sekiguchi, F., Nishikawa, H. and Kawabata, A.* (2013) Contribution of TRPA1 as a downstream signal of proteinase-activated receptor-2 to pancreatic pain. J. Pharmacol. Sci., 123, 284-287. PubMed

83. Tanaka, J., Seki, Y., Ishikura, H., Tsubota, M., Sekiguchi, F., Yamaguchi, K., Murai, A., Umemura, T. and Kawabata, A.* (2013) Recombinant human soluble thrombomodulin prevents peripheral HMGB1-dependent hyperalgesia in rats. Br. J. Pharmacol., 170, 1233-1241. PubMed

84. Sekiguchi, F. and Kawabata, A.* (2013) T-type calcium channels: functional regulation and implication in pain signaling. J. Pharmacol. Sci., 122, 244-250. PubMed (Review)

85. Nishikawa, H., Hayashi, H., Kubo, S., Tsubota-Matsunami, M., Sekiguchi, F., and Kawabata, A.* (2013) Inhibition by hydrogen sulfide of rabbit platelet aggregation and calcium mobilization. Biol. Pharm. Bull., 36, 1278-1282. PubMed

86. Nakayama, M.*, Fujiwara, M., Nakamura, T., Azuma, T., Matzno, S., Kamikonya, N., Kimura, T., Matsuyama, K., Kawabata, A. (2013) Stability of polaprezinc-containing oral rinse and its clinical effectiveness against radiotherapy-induced oral mukcositis. Jpn. J. Drug Inform., 15, 133-138.

87. Nakayama, M.*, Nakamura, T., Azuma, T., Shikata, T., Kawabata, A., Matsuyama, K., Fujiwara, M., Kamikonya, N., Kimura, T. (2013) Examination of a new base for the polaprezinc oral rinse. Jpn. J. Drug Inform. Jpn. J. Drug Inform., 15, 13-17.

88. Takahashi, T., Okubo, K., Kojima, S., Nishikawa, H., Takemura, M., Tsubota-Matsunami, M., Sekiguchi, F. and Kawabata, A.* (2013) Antihyperalgesic effect of buprenorphine involves nociceptin/orphanin FQ peptide receptor activation in rats with spinal nerve injury-induced neuropathy. J. Pharmacol. Sci., in press. PubMed

89. Kawabata, A.* (2013) Targeting Cav3.2 T-type calcium channels as a therapeutic strategy for chemotherapy-induced neuropathic pain. Nihon Yakurigaku Zasshi, 141, 81-84. PubMed (Review)

90. Sekiguchi, F., Aoki, Y., Nakagawa, M., Kanaoka, D., Nishimoto, Y., Tsubota-Matsunami, M., Yamanaka, R., Yoshida, S. and Kawabata, A.* (2013) AKAP-dependent sensitization of Cav3.2 channels via the EP4 receptor/cyclic AMP pathway mediates prostaglandin E2-induced mechanical hyperalgesia. Br. J. Pharmacol., 168, 734-745. PubMed

91. Sekiguchi, F., Matsumoto, Y., Maeda, Y., Tsubota-Matsunami, M., Nishikawa, H. and Kawabata, A.* (2012) Biological activity of Helicobactor pylori components in mammalian cells: is it independent of proteinase-activated recetpros? J. Physiol. Pharmacol., 63, 571-576. PubMed

92. Tsubota-Matsunami, M., Noguchi, Y., Okawa, Y., Sekiguchi, F. and Kawabata, A.* (2012) Colonic hydrogen sulfide-induced visceral pain and referred hyperalgesia involve activation of both Cav3.2 and TRPA1 channels in mice. J. Pharmacol. Sci., 119, 293-296. PubMed

93. Matsunami, M., Miki, T., Nishiura, K., Hayashi, Y., Okawa, Y., Nishikawa, H., Sekiguchi, F., Kubo, L., Ozaki, T., Tsujiuchi, T. and Kawabata, A.* (2012) Involvement of the endogenous hydrogen sulfide/Cav3.2 T-type Ca2+ channel pathway in cystitis-related bladder pain in mice. Br. J. Pharmacol., 167, 917-928. PubMed

94. Kawabata, A.* and Matsunami, M. (2012) Roles of the hydrogen sulfide/T-type calcium channel system in somatic and visceral pain processing. In Cell/Tissue Injury and Cytoprotection/Organoprotection in the Gastrointestinal Tract: Mechanisms, Prevention and Treatment, edited by Filaretova, L.P. and Takeuchi, K., Front. Gastrointest. Res., Basel, Karger (vol 30), pp212-218. (Book Chapter)

95. Matsunami, M., Kirishi, S., Okui, T. and Kawabata, A.* (2012) Hydrogen sulfide-induced colonic mucosal cytoprotection involves T-type calcium channel-dependent neuronal excitation in rats. J. Physiol. Pharmacol., 63, 61-68. PubMed

96. Okubo, K., Matsumura, M., Kawaishi, Y., Aoki, Y., Matsunami, M., Okawa, Y., Sekiguchi, F. and Kawabata, A.* (2012) Hydrogen sulfide-induced mechanical hyperalgesia and allodynia require activation of both Cav3.2 and TRPA1 channels in mice. Br. J. Pharmacol., 166, 1738-1743. PubMed

97. Okubo, K., Nakanishi, H., Matsunami, M., Shibayama, H. and Kawabata, A.* (2012) Topical application of disodium isostearyl 2-O-L-ascorbyl phosphate, an amphiphilic ascorbic derivative, reduces neuropathic hyperalgesia in rats. Br. J. Pharmacol., 166, 1058-1068. PubMed

98. Kurokawa, Y., Sekiguchi, F., Kubo, S., Yamasaki, Y., Matsuda, S., Okamoto, Y., Sekimoto, T., Fukatsu, A., Nishikawa, H., Kume, T., Fukushima, N., Akaike, A. and Kawabata, A.* (2011) Involvement of ERK in NMDA receptor-independent cortical neurotoxicity of hydrogen sulfide. Biochem. Biophys. Res. Commun., 414, 727-732. PubMed

99. Okubo, K. and Kawabata A.* (2011) Roles of hydrogen sulfide in neuropathic painDPain Clinic, 32, 1464-1471. (Review)

100.          Okubo, K., Takahashi, T., Sekiguchi, F., Kanaoka, D., Matsunami, M., Ohkubo, T., Yamazaki, J., Fukushima, N., Yoshida, S. and Kawabata, A.* (2011) Inhibition of T-type calcium channels and hydrogen sulfide-forming enzyme reverses paclitaxel-evoked neuropathic hyperalgesia in rats. Neuroscience, 188, 148-156. PubMed

101.          Matsunami, M., Kirishi, S., Okui, T. and Kawabata, A.* (2011) Chelating luminal zinc mimics hydrogen sulfide-evoked colonic pain in mice: possible involvement of T-type calcium channels. Neuroscience, 181: 257-264. PubMed

102.          Miki, T., Matsunami, M., Nakamura, S., Okada, H., Matsuya, H. and Kawabata, A.* (2011) ONO-8130, a selective prostanoid EP1 receptor antagonist, relieves bladder pain in mice with cyclophosphamide-induced cystitis. Pain, 152, 1373-1381. PubMed

103.          Kawabata, A.* (2011) Prostaglandin E2 and pain: an update. Biol. Pharm. Bull., 34, 1170-1173. (Review)  PubMed

104.          Kawabata, A.* (2011) Lipid Mediators and Pain Signaling: Foreword. Biol. Pharm. Bull., 34, 1153. (Foreword)  PubMed

105.          Sekiguchi, F., Ohi, A., Maeda, Y., Takaoka, K., Sekimoto, T., Nishikawa, H. and Kawabata, A.* (2011) Delayed production of arachidonic acid contributes to the delay of proteinase-activated receptor-1 (PAR1)-triggered prostaglandin E2 release in rat gastric epithelial RGM1 cells. J. Cell. Biochem., 112, 909-1015. PubMed 

106.          Nishimura, S. Ishikura, H., Matsunami, M., Shinozaki, Y., Sekiguchi, F., Naruse, M., Kitamura, T., Akashi, R., Matsumura, K. and Kawabata, A.* (2010) The proteinase/proteinase-activated receptor-2/transient receptor potential vanilloid-1 cascade impacts pancreatic pain in mice. Life Sci., 87, 643-650. PubMed

107.          Moriyuki, K., Sekiguchi, F., Matsubara, K., Nishikawa, H. and Kawabata, A.* (2010) Curcumin inhibits the proteinase-activated receptor-2-triggered prostaglandin E2 production by suppressing COX-2 upregulation and Akt-dependent activation of NF-ƒΘB in human lung epithelial cells. J. Pharmacol. Sci., 114, 225-229. PubMed

108.          Fukushima, O., Nishimura, S., Matsunami, M., Aoki, Y., Nishikawa, H., Ishikura, H. and Kawabata, A.* (2010) Phosphorylation of ERK in the spinal dorsal horn following pancreatic pro-nociceptive stimuli with proteinase-activated receptor-2 agonists and hydrogen sulfide in rats: evidence for involvement of distinct mechanisms. J. Neurosci. Res., 88, 3198-3205. PubMed

109.          Tarui, T., Fukami, K., Nagasawa, K., Yoshida, S., Sekiguchi, F. and Kawabata, A.* (2010) Involvement of Src kinase in T-type calcium channel-dependent neuronal differentiation of NG108-15 cells by hydrogen sulfide. J. Neurochem., 114, 512-519. PubMed

110.          Takahashi, T., Aoki, Y., Okubo, K., Maeda, Y., Sekiguchi, F., Mitani, K., Nishikawa, H. and Kawabata, A.* (2010) Upregulation of Cav3.2 T-type calcium channels targeted by endogenous hydrogen sulfide contributes to maintenance of neuropathic pain. Pain, 150, 183-191. PubMed

111.          Takaoka, K., Sekiguchi, F., Shigi, H., Maeda, Y., Nishikawa, H. and Kawabata, A.* (2010) Opposite effects of two thiazolidinediones, ciglitazone and troglitazone, on proteinase-activated receptor-1-triggered prostaglandin E2 release. Toxicology, 268, 40-45. PubMed

112.          Moriyuki, K., Sekiguchi, F., Matsubara, K., Nishikawa, H. and Kawabata, A.* (2009) PAR2-triggered prostaglandin E2 release, but not cyclooxygenase-2 upregulation, requires activation of the phosphatidylinositol 3-kinase/Akt/NFƒΘB pathway in human alveolar epithelial cells. J. Pharmacol. Sci., 111, 269-275. PubMed

113.          Kanke, T., Kabeya, M., Kubo, S., Kondo, S., Yasuoka, K., Tagashira, J., Ishiwata, H., Saka, M., Furuyama, T., Nishiyama, T., Doi, T., Hattori, Y., Kawabata, A., Cunningham, M., Plevin, R.* (2009) Novel antagonists for proteinase-activated receptor 2: inhibition of cellular and vascular responses in vitro and in vivo. Br. J. Pharmacol.,158, 361-371. PubMed

114.          Taniguchi, E., Matsunami, M., Kimura, T., Yonezawa, D., Ishiki, T., Sekiguchi, F., Nishikawa, H., Maeda, Y., Ishikura, H., Kawabata, A.* (2009) Rhodanese, but not cystathionine-ƒΑ-lyase, is associated with dextran sulfate sodium-evoked colitis in mice: a sign of impaired colonic sulfide detoxification? Toxicology, 264, 96-103. PubMed

115.          Kawabata, A.* (2009) Neuronal functions of hydrogen sulfide as a gaseous mediator. Brain21, 12, 239-245. (Review)

116.          Nishimura, S., Fukushima, O., Ishikura, H., Takahashi, T., Matsunami, M., Tsujiuchi, T., Sekiguchi, F., Naruse, M., Kamanaka, Y. and Kawabata, A.* (2009) Hydrogen sulfide as a novel mediator for pancreatic pain in rodents. Gut, 58, 762-770. PubMed Outstanding paper

117.          Maeda, Y., Aoki, Y., Sekiguchi, F., Matsunami, M., Takahashi, T., Nishikawa, H. and Kawabata, A.* (2009) Hyperalgesia induced by spinal and peripheral hydrogen sulfide: evidence for involvement of Cav3.2 T-type calcium channels. Pain, 142, 127-132. PubMed

118.          Nagasawa, K., Tarui, T., Yoshida, S., Sekiguchi, F., Matsunami, M., Ohi, A., Fukami, K., Ichida, S., Nishikawa, H. and Kawabata, A.* (2009) Hydrogen sulfide evokes neurite outgrowth and expression of high-voltage-activated Ca2+ currents in NG108-15 cells: involvement of T-type Ca2+ channels. J. Neurochem., 108, 676-684. PubMed

119.          Matsunami, M., Tarui, T., Mitani, K., Nagasawa, K., Fukushima, O., Okubo, K., Yoshida, S., Takemura, M. and Kawabata, A.* (2009) Luminal hydrogen sulfide plays a pronociceptive role in mouse colon. Gut, 58, 751-761. PubMed Outstanding paper

120.          Hirano, K.* and Kawabata, A. (2008) Basic and translational research on proteinase-activated receptors: Preface. J. Pharmacol. Sci., 108, 406-407. PubMed (Preface)

121.          Tanaka, Y., Sekiguchi, F., Hong, H. and Kawabata, A.* (2008) PAR2 triggers IL-8 release via MEK/ERK and PI3-kinase/Akt pathways in GI epithelial cells. Biochem. Biophys. Res. Commun., 377, 622-626. PubMed

122.          Sekiguchi, F. and Kawabata, A. (2008) Protease-activated receptor signals. Kyukyu, Shuchu Chiryo, 20 (9-10), 1297-1303. (Review)

123.          Kawabata, A.*, Matsunami, M. and Sekiguchi, F. (2008) Gastrointestinal roles for proteinase-activated receptors in health and disease. Br. J. Pharmacol., 153, S230-S240. (Review) PubMed

124.          Nagataki, M., Moriyuki, K., Sekiguchi, F. and Kawabata, A.* (2008) Evidence that PAR2-triggered prostaglandin E2 (PGE2) formation involves the ERK-cytosolic phospholipase A2-COX-1-microsomal PGE synthase-1 cascade in human lung epithelial cells. Cell Biochem. Funct., 26, 279-282. PubMed

125.          Moriyuki, K., Nagataki, M., Sekiguchi, F., Nishikawa, H. and Kawabata, A.* (2008) Signal transduction for formation/release of interleukin-8 caused by a PAR2-activating peptide in human lung epithelial cells. Regul. Pept, 145, 42-48. PubMed

126.          Kubo, S., Kurokawa, Y., Doe, I., Masuko, T., Sekiguchi, F. and Kawabata, A.* (2007) Hydrogen sulfide inhibits activity of three isoforms of recombinant nitric oxide synthase. Toxicology, 241, 92-97.

127.          Matsunami, M. and Kawabata, A.* (2007) Is H2S considered a nociceptive mediator? Nihon Yakurigaku Zasshi, 130, 436-437. (Review: Recent topics)

128.          Yonezawa, D., Sekiguchi, F., Miyamoto, M., Taniguchi, E., Honjo, M., Masuko, T., Nishikawa, H. and Kawabata, A.* (2007) A protective role of hydrogen sulfide against oxidative stress in rat gastric mucosal epithelium. Toxicology, 241, 11-18.

129.          Kubo, S., Doe, I., Kurokawa, Y. and Kawabata, A.* (2007) Hydrogen sulfide causes relaxation in mouse bronchial smooth muscle. J. Pharmacol. Sci., 104, 392-396.

130.          Kawabata, A.* (2007) Roles for H2S in Pain Processing: Response to Cunha and Verri. Pain, 130, 302-303.

131.          Ishikura, H., Nishimura, S., Matsunami, M., Tsujiuchi, T., Ishiki, T., Sekiguchi, F., Naruse, M., Nakatani, T., Kamanaka, Y. and Kawabata, A.* (2007) The proteinase inhibitor camostat mesilate suppresses pancreatic pain in rodents. Life Sci., 80, 1999-2004.

132.          Kawabata, A.*, Ishiki, T., Nagasawa, K., Yoshida, S., Maeda, Y., Takahashi, T., Sekiguchi, F., Wada, T., Ichida, S. and Nishikawa, H. (2007) Hydrogen sulfide as a novel nociceptive messenger. Pain, 132, 74-81.

133.          Kubo, S., Doe, I., Kurokawa, Y., Nishikawa, H. and Kawabata, A.* (2007) Direct inhibition of endothelial nitric oxide synthase by hydrogen sulfide: contribution to dual modulation of vascular tension. Toxicology, 232, 138-146.

134.          Sekiguchi, F., Saito, S., Takaoka, K., Hayashi, H., Nagataki, M., Nagasawa, K., Nishikawa, H., Matsui, H. and Kawabata, A.* (2007) Mechanisms for prostaglandin E2 formation caused by proteinase-activated receptor-1 activation in rat gastric mucosal epithelial cells. Biochem. Pharmacol., 73, 103-114.

135.          Kubo, S., Ishiki, T., Doe, I., Sekiguchi, F., Nishikawa, H., Kawai, K., Matsui, H. and Kawabata, A.* (2006) Distinct activity of peptide mimetic intracellular ligands (pepducins) for proteinase-activated receptor-1 in multiple cells/tissues. Ann. NY Acad. Sci., 1091, 445-459.

136.          Matsunami, M., Sekiguchi, F. and Kawabata, A.* (2006) Proteinase-activated receptor (PAR). Nihon Yakurigaku Zasshi, 128, 434-436. (Review).

137.          Kawabata, A.* (2006). Proteinase-activated receptors and gastrointestinal functions. Nihon Yakurigaku Zasshi, 128, 82-87. (Review).

138.          Kawabata, A.*, Kawao, N., Kitano, T., Matsunami, M., Satoh, R., Ishiki, T., Masuko, T., Kanke, T. and Saito N. (2006). Colonic hyperalgesia triggered by proteinase-activated receptor-2 in mice: involvement of endogenous bradykinin. Neurosci. Lett., 402, 167-172.

139.          Kawabata, A.*, Kawao, N., Hironaka, Y., Ishiki, T., Matsunami, M. and Sekiguchi, F. (2006). Antiallodynic effect of etidronate, a bisphosphonate, in rats with adjuvant-induced arthritis: involvement of ATP-sensitive K+ channels. Neuropharmacology, 51, 182-190.

140.          Kawabata, A.*, Matsunami, M., Tsutsumi, M., Ishiki, T., Fukushima, O., Sekiguchi, F., Kawao, N., Minami, T., Kanke, T. and Saito, N. (2006) Suppression of pancreatitis-related allodynia/hyperalgesia by proteinase-activated receptor-2 in mice. Br. J. Pharmacol., 148, 54-60.

141.          Kawabata, A.* (2006) PAR-2 and pain. Nihon Yakurigaku Zasshi, 127, 133-136. (Review)

142.          Sekiguchi, F., Hasegawa, N., Inoshita, K., Yonezawa, D., Inoi, N., Kanke, T., Saito, N. and Kawabata, A.* (2006) Mechanisms for modulation of mouse gastrointestinal motility by proteinase-activated receptor (PAR)-1 and -2 in vitro. Life Sci., 78, 950-957.

143.          Kawao, N., Nagataki, M., Nagasawa, K., Kubo, S., Cushing, K., Wada, T., Sekiguchi, F., Ichida, S., Hollenberg, M.D., MacNaughton, W.K., Nishikawa, H. and Kawabata, A.* (2005) Signal transduction for proteinase-activated receptor-2-triggered prostaglandin E2 formation in human lung epithelial cells. J. Pharmacol. Exp. Ther., 315, 576-589.

144.          Nishikawa, H. and Kawabata, A.* (2005) PAR-2 as a target for gastric mucosal protection. Drugs of Future, 30, 793-798. (Review)

145.          Kawabata, A.* (2005) Involvement of sensory nerves/TRPV1 in acute pancreatitis and. J. Gastrointestinal Res., 13, 387-392.. (Review)

146.          Nishikawa, H. and Kawabata, A.* (2005) Modulation by PARs of gastrointestinal functions. Surgery Frontier , 12, 135-143. (Review)

147.          Sekiguchi, F.* (2005). Development of agonists/antagonists for protease-activated receptors (PARs) and the therapeutic possibility to gastrointestinal diseases. Yakugaku Zasshi, 125, 491-498. (Review)

148.          Kanke, T.*, Ishiwata, H., Kabeya, M., Saka, M., Doi, T., Hattori, Y., Kawabata, A. and Plevin, R. (2005) Binding of a highly potent protease-activated receptor-2 (PAR2) activating peptide, [3H]-2-furoyl-LIGRL-NH2, to human PAR2. Br. J. Pharmacol., 145, 255-263.

149.          Kawabata, A.*, Oono, Y., Yonezawa, D., Hiramatsu, K., Inoi, N., Sekiguchi, F., Honjo, M., Hirofuchi, M., Kanke, T. and Ishiwata, H. (2005) 2-furoyl-LIGRL-NH2, a potent agonist for proteinase-activated receptor-2, as a gastric mucosal cytoprotective agent. Br. J. Pharmacol., 144, 212-219.

150.          Kawabata, A.* and Kawao, N. (2005) Physiology and pathophysiology of proteinase-activated receptors (PARs): PARs in the respiratory system: cellular signaling and physiological/pathological roles. J. Pharmacol. Sci., 97, 20-24. (Review)

151.          Kanke, T.*, Takizawa, T., Kabeya, M. and Kawabata, A. (2005) Physiology and pathophysiology of proteinase-activated receptors (PARs): Proteinase-activated receptor-2 (PAR-2) as a potential therapeutic target. J. Pharmacol. Sci., 97, 38-42. (Review)

152.          Nishikawa, H., Kawai, K., Tanaka, M., Ohtani, H., Tanaka, S., Kitagawa, C., Nishida, M., Abe, T., Araki, H. and Kawabata, A.* (2005). Protease-activated receptor-2 (PAR-2)-related peptides induce tear secretion in rats: involvement of PAR-2 and non-PAR-2 mechanisms. J. Pharmacol. Exp. Ther., 312, 324-331.

153.          Kimura, T., Arai, M., Masuda, H. and Kawabata, A.* (2004). Impact of a pharmacist-implemented anemia management in outpatients with end-stage renal disease in Japan. Biol. Pharm. Bull., 27, 1831-1833

154.          Kawabata, A.*, Nakaya, Y., Ishiki, T., Kubo, S., Kuroda, R., Sekiguchi, F., Kawao, N., Nishikawa, H. (2004) Receptor-activating peptides for PAR-1 and PAR-2 relax rat gastric artery via multiple mechanisms. Life Sci., 75, 2689-2702.

155.          Sekiguchi, F. and Kawabata, A.* (2004) Protease-activated receptors (PARs) as therapeutic targets: development of agonists/antagonists and modulation of gastrointestinal functions. Drug Design Reviews, 1, 287-296. (Review)

156.          Kawabata, A.* (2004) PAR (protease-activated receptor). Seitai-No-Kagaku 55, 520-521. (Review)

157.          Kawabata, A.*, Kubo, S., Ishiki, T., Kawao, N., Sekiguchi, F., Kuroda, R., Hollenberg, M.D., Kanke, T. and Saito N. (2004) Proteinase-activated receptor-2-mediated relaxation in mouse tracheal and bronchial smooth muscle: Signal transduction mechanisms and distinct agonist sensitivity. J. Pharmacol. Exp. Ther., 311, 402-410.

158.          Kawabata, A.*, Itoh, H., Kawao, N., Kuroda, R., Sekiguchi, F., Masuko, T., Iwata, K., Ogawa, A. (2004). Activation of trigeminal nociceptive neurons by parotid PAR-2 activation in rats. NeuroReport, 15, 1617-1621.

159.          Sekiguchi, F., Mita, Y., Kamanaka, Y., Kawao, N., Matsuya, H., Taga, C. and Kawabata, A.* (2004). The potent iNOS inhibitor ONO-1714 inhibits nNOS and exerts antinociception in rats. Neurosci. Lett., 365, 111-115.

160.          Kawabata, A*, Kanke, T., Yonezawa, D., Ishiki, T., Saka, M., Kabeya, M., Sekiguchi, F., Kubo, S., Kuroda, R., Iwaki, M., Katsura, K. and Plevin, R (2004) Potent and metabolically stable agonists for protease-activated receptor-2: Evaluation of activity in multiple assay systems in vitro and in vivo. J. Pharmacol. Exp. Ther. 309, 1098-1107.

161.          Kawao, N., Ikeda, H., Kitano, T., Kuroda, R., Sekiguchi, F., Kataoka, K., Kamanaka, Y. and Kawabata, A.* (2004) Modulation of capsaicin-evoked visceral pain and referred hyperalgesia by protease-activated receptors 1 and 2. J. Pharmacol. Sci. 61, 683-692.

162.          Kawabata, A.*, Kubo, S., Nakaya, Y., Ishiki, T., Kuroda, R., Sekiguchi, F., Kawao, N. and Nishikawa, H. (2004). Distinct roles for protease-activated receptors 1 and 2 in vasomotor modulation in rat superior mesenteric artery. Cardiovasc. Res. 61, 683-692.

163.          Kawabata, A.*, Nishikawa, H., Saitoh, H., Nakaya, Y., Hiramatsu, K., Kubo, S., Nishida, M., Kawao, N., Kuroda, R., Sekiguchi, F., Kinoshita, M., Kakehi, K., Arizono, N., Yamagishi, H. and Kawai, K. (2004) A protective role of protease-activated receptor-1 in rat gastric mucosa. Gastroenterology 126, 208-219. Breakthrough paper

164.          Kawao, N., Hiramatsu, K., Inoi, N., Kuroda, R., Nishikawa, H., Sekiguchi, F. and Kawabata, A.* (2003) The PAR-1-activating peptide facilitates pepsinogen secretion in rats. Peptides 24, 1449-1451.

165.          Kamanaka, Y., Kawabata, A.*, Matsuya, H., Taga, C., Sekiguchi, F. and Kawao, N. (2003) Effect of a potent iNOS inhibitor (ONO-1714) on acetaminophen-induced hepatotoxicity in the rat. Life Sci. 74, 793-802.

166.          Kawabata, A.*, Nakaya, Y., Kuroda, R., Wakisaka, M., Masuko, T., Nishikawa, H. and Kawai, K. (2003) Involvement of EDHF in the hypotension and increased gastric mucosal blood flow caused by PAR-2 activation in rats. Br. J. Pharmacol. 140, 247-254.

167.          Kuroda, R.*, Kawabata, A.  (2003) Pain information pathways from the periphery to the cerebral cortex. Yakugaku Zasshi 123, 533-546 (Review) (in Japanese)

168.          Kawabata, A.* (2003) Gastrointestinal functions of proteinase-activated receptors. Life Sci. 74, 247-254. (Review)

169.          Kawabata, A.* and Kawao, N. (2003) Protease-activated receptors and inflammation. BIO Clinica 18, 551-555. (Review) (in Japanese).

170.          Nishikawa, H. and Kawabata, A.* (2003) Modulation of gastric functions by PARs. Drug Dev. Res. 60, 9-13. (Review)

171.          Kawabata, A.* (2003) Physiological functions of protease-activated receptor-2. Folia Pharmacol. Japon 121, 411-420. (Review) (in Japanese).

172.          Kawabata, A.* (2002) Multiple roles for protease-activated receptor-2 in gastric mucosa. Inflammopharmacology 10, 343-349. (Review)

173.          Kawabata, A.* (2002) Protease-activated receptor-2 (PAR-2): roles in the nervous, gastrointestinal and circulatory systems. Hemostasis 13, 467-476. (Review) (in Japanese).

174.          Kawabata, A.*, and Kuroda,  R. (2002) PAR (protease-activated receptor) as a novel target for development of gastric mucosal cytoprotective drugs. Folia Pharmacol. Japon. 120 (Suppl.), 85P-87P. (Review) (in Japanese).

175.          Kawabata, A.*, Kuroda, R., Nishida, M., Nagata, N., Sakaguchi, Y., Kawao, N., Nishikawa, H., Arizono, N. and Kawai, K. (2002) Protease-activated receptor-2 (PAR-2) in the pancreas and parotid gland: immunolocalization and involvement of nitric oxide in the evoked amylase secretion. Life Sci. 71, 2435-2446.

176.          Kawabata, A.*, Kawao, N., Itoh, H., Shimada, C., Takebe, K., Kuroda, R., Masuko, T., Kataoka, K. and Ogawa, S. (2002) Role of N-methyl-D-aspartate receptors and the nitric oxide pathway in nociception/hyperalgesia elicited by PAR-2 activation in mice and rats. Neurosci. Lett. 329, 349-353.

177.          Kawabata, A.* (2002) PAR (protease-activated receptor). Seitai-No-Kagaku 53, 345. (Mini Review) (in Japanese).

178.          Nishikawa, H., Kawai, K., Nishimura, S., Tanaka, S., Araki, H., Al-Ani, B., Hollenberg, M.D., Kuroda, R. and Kawabata, A.* (2002) Suppression by protease-activated receptor-2 activation of gastric acid secretion in rats. Eur. J. Pharmacol. 447, 87-90.

179.          Gojyo, F., Sugiyo, S., Kuroda, R., Kawabata, A., Varathan, V., Shigenaga, Y. and Takemura, M.* (2002) Effects of somatosensory cortical stimulation on expression of c-Fos in rat medullary dorsal horn in response to formalin-induced noxious stimulation. J. Neurosci. Res., 68, 479-488.

180.          Kawabata, A.* (2002) PAR-2: structure, function and relevance to human diseases of the gastric mucosa. Expert Reviews in Molecular Medicine (a Web journal published by Cambridge University Press), 16 July, http://www.expertreviews.org/02004799h.htm. (Review)

181.          Kawao, N., Shimada, C., Itoh, H., Kuroda, R. and Kawabata, A.* (2002) Capsazepine inhibits thermal hyperalgesia but not nociception triggered by protease-activated receptor-2 in rats. Jpn. J. Pharmacol., 135, 1292-1296.

182.          Kawabata, A.*, Kawao, N., Kuroda, R., Tanaka, A. and Shimada, C. (2002) The PAR-1-activating peptide attenuates carrageenan-induced hyperalgesia in rats. Peptides, 23, 1181-1183.

183.          Kawao, N., Sakaguchi, Y., Tagome, A., Kuroda, R., Nishida, S., Irimajiri, K., Nishikawa, H., Kawai, K., Hollenberg, M.D., and Kawabata, A.* (2002) Protease-activated receptor-2 in the rat gastric mucosa: immunolocalization and facilitation of pepsin/pepsinogen secretion. Br. J. Pharmacol., 135, 1292-1296.

184.          Kawabata, A.*, Kawao, N., Kuroda, R., Itoh, H. and Nishikawa, H. (2002) Specific expression of spinal Fos after PAR-2 stimulation in mast cell-depleted rats. NeuroReport, 13, 511-514.

185.          Kawabata, A.*, Kinoshita, M., Kuroda, R. and Kakehi, K. (2002) Capsazepine partially inhibits the neurally mediated gastric mucus secretion following activation of protease-activated receptor-2. Clin. Exp. Pharmacol. Physiol., 29, 360-361

186.          Morimoto, N., Nakano, M., Kinoshita, M., Kawabata, A., Morita, M., Oda, Y., Kuroda, R. and Kakehi, K.* (2001) Specific distribution of sialic acids in animal tissues as examined by LC-ESI-MS after derivatization with 1,2-diamino-4,5-methylenedioxybenzene. Anal. Chem. 73, 5422-5428.

187.          Kawabata, A.*, Kuroda, R., Nagata, N., Kawao, N., Masuko, T., Nishikawa, H. and Kawai, K. (2001) In vivo evidence that protease-activated receptors 1 and 2 modulate gastrointestinal transit in the mouse. Br. J. Pharmacol. 133, 1213-1218.

188.          Kawabata, A.*, Kuroda, R., Morimoto, N., Kawao, N., Masuko, T., Kakehi, K., Kataoka, K., Taneda, M., Nishikawa, H. and Araki, H. (2001) Lipopolysaccharide-induced subsensitivity of protease-activated receptor-2 in the mouse salivary glands in vivo. Naunyn-Schmiedebergfs Arch. Pharmacol. 364, 281-284.

189.          Kawabata, A.*, Kinoshita, M., Nishikawa, H., Kuroda, R., Nishida, M., Araki, H., Arizono, N., Oda, Y. and Kakehi, K. (2001) The protease-activated receptor-2 agonist induces gastric mucus secretion and mucosal cytoprotection. J. Clin. Invest. 107, 1443-1450. Breakthrough paper

190.          Kuroda, R., Kawao, N., Yoshimura, H., Umeda, W., Takemura, M., Shigenaga, Y. and Kawabata, A.* (2001) Secondary somatosensory cortex stimulation facilitates the antinociceptive effect of the NO synthase inhibitor through suppression of spinal nociceptive neurons in the rat. Brain Res. 903, 110-116.

191.          Kawabata, A.*, Kuroda, R., Nakaya, Y., Kawai, K., Nishikawa, H. and Kawao, N. (2001) Factor Xa-evoked relaxation in rat aorta: involvement of PAR-2. Biochem. Biophys. Res. Commun. 282, 432-435.

192.          Kawabata, A.*, Kawao, N., Kuroda, R., Tanaka, A., Itoh, H. and Nishikawa, H. (2001) Peripheral PAR-2 triggers thermal hyperalgesia and nociceptive responses in rats. NeuroReport 12, 715-719.

193.          Kawabata, A.*, Kuroda, R., Nakaya, Y., Kawao, N. Nishikawa, H. (2001) Ex vivo evidence that the phosphodiesterase inhibitor IBMX attenuates the up-regulation of PAR-2 in the endotoxemic rat aorta. Thromb. Res. 101, 513-515.

194.          Kawabata, A.* (2001) The G protein-coupled protease receptor PAR  (protease-activated receptor) as a novel target for drug development. Yakugaku Zasshi 121, 1-7. (Review)

195.          Kataoka, K.*, Asai, T., Taneda, M., Ueshima, S., Matsuo, O., Kuroda, R., Kawabata, A. and Carmeliet, P. (2000) Roles of urokinase type plasminogen activator in a brain stab wound. Brain Res. 887, 187-190.

196.          Kawabata, A.*, Kuroda, R., Kuroki, N., Nishikawa, H. and Kawai, K. (2000) Dual modulation by thrombin of the motility of rat oesophageal muscularis mucosae via two distinct protease-activated receptors (PARs): a novel role for PAR-4 as opposed to PAR-1. Br. J. Pharmacol. 131, 578-584.

197.          Kinoshita, M., Inagake, K., Kawabata, A., Kuroda, R., Oda, Y. and Kakehi, K.* (2000) Fluorometric determination of mucin-type glycoproteins by the galactose oxidase-peroxidase method. Anal. Biochem. 284, 87-92.

198.          Kawabata, A., Morimoto, N., Oda, Y., Kinoshita, M., Kuroda, R. and Kakehi, K.* (2000) Determination of mucin in salivary glands using sialic acids as the marker by high performance liquid chromatography with fluorometric detection. Anal. Biochem. 283, 119-121.

199.          Kawabata, A.*, Kuroda, R., Kuroki, N., Nishikawa, H., Kawai, K. and Araki, H. (2000) Characterization of the protease-activated receptor-1-mediated contraction and relaxation in the rat duodenal smooth muscle. Life Sci. 67, 2521-2530.

200.          Kawabata, A.*, Nishikawa, H., Kuroda, R., Kawai, K. and Hollenberg, M.D. (2000) Proteinase-activated receptor-2 (PAR-2): regulation of salivary and pancreatic exocrine secretion in vivo in rats and mice. Br. J. Pharmacol. 129, 1808-1814.

201.          Kawabata, A.*, Morimoto, N., Nishikawa, H., Kuroda, R., Oda, Y. and Kakehi, K. (2000) Activation of protease-activated receptor-2 (PAR-2) triggers mucin secretion in the rat sublingual gland. Biochem. Biophys. Res. Commun. 270, 298-302.

202.          Kuroda, R., Kawabata, A.*, Kawao, N., Umeda, W., Takemura, M. and Shigenaga, Y. (2000) Somatosensory cortex stimulation-evoked analgesia in rats: potentiation by NO synthase inhibition.  Life Sci. 66,  PL271-PL276.

203.          Nishikawa, H., Kawabata, A.*, Kawai, K. and Kuroda, R. (2000) Guinea pig platelets do not respond to GYPGKF, a protease-activated receptor-4-activating peptide: a property distinct from human platelets.  Blood Coag. Fibrinol. 11, 111-113.

204.          Kawabata, A.* and Kuroda, R. (2000) Protease-activated receptor (PAR), a novel family of G protein-coupled seven trans-membrane domain receptors: activation mechanisms and physiological roles. Jpn. J. Pharmacol. 82, 171-174. (Review)

205.          Nishikawa, H., Kawabata, A.*, Kuroda, R., Nishida, M. and Kawai, K. (2000) Characterization of protease-activated receptors in rat peritoneal mast cells.  Jpn. J. Pharmacol. 82, 74-77.

206.          Kawabata, A.*, Kuroda, R., Nishikawa, H. and Kawai, K. (1999) Modulation by protease-activated receptors of the rat duodenal motility in vitro: possible mechanisms underlying the evoked contraction and relaxation. Br. J. Pharmacol. 128, 865-872.

207.          Kawabata, A.*, Kuroda,  R. and Hollenberg, M.D. (1999) Physiology of protease-activated receptors (PARs): involvement of PARs in digestive functions. Nihon Yakurigaku Zasshi, 114 (Suppl.), 173P-179P. (Review) (in Japanese).

208.          Kawabata, A.*, Kuroda, R., Nishikawa, H., Asai, T., Kataoka, K. and Taneda, M. (1999) Enhancement of vascular permeability by specific activation of protease-activated receptor-1 in rat hindpaw: a protective role of endogenous and exogenous nitric oxide.  Br. J. Pharmacol. 126, 1856-1862.

209.          Al-Ani, B., Saifeddine, M., Kawabata, A. and Hollenberg, M.D.* (1999) Proteinase activated receptor 2: role of extracellular loop 2 for ligand-mediated activation.  Br. J. Pharmacol. 128, 1105-1113.

210.          Al-Ani, B., Saifeddine, M., Kawabata, A., Renaux, B., Mokashi, S. and Hollenberg, M.* (1999) Proteinase-activated receptor-2 (PAR2): development of a ligand binding assay correlating with activation of PAR2 by PAR1- and PAR2-derived peptide ligands.  J. Pharmacol. Exp. Ther. 290, 753-760.

211.          Kawabata, A., Saifeddine, M., Al-Ani, B., Leblond, L. and Hollenberg, M.D.* (1999) Evaluation of proteinase-activated receptor-1 (PAR1) agonists and antagonists using a cultured cell receptor desensitization assay: Activation of PAR2 by PAR1-targeted ligands.  J. Pharmacol. Exp. Ther. 288, 358-370.

212.          Kawabata, A.*, Kuroda, R., Minami, T., Kataoka, K. and Taneda, M. (1998) Increased vascular permeability by a specific agonist of protease-activated receptor-2 in rat hindpaw.  Br. J. Pharmacol. 125, 419-422.

213.          Minami, T.*, Okazaki, J., Kawabata, A., Kuroda, R. and Okazaki, Y. (1998) Penetration of cisplatin into mouse brain by lipopolysaccharide.  Toxicology 130, 107-113.

214.          Kawabata, A.*, Hata, T., Kuroda, R. (1998) Cross tolerance to environmental stress and endotoxin.  Life Sci. 62, PL327-PL333.

215.          Kawabata, A., Murakami, E., Iwaki, M., Ogiso, T., Suzuki, S., Mishima, M., Takada, M. and Kakehi, K.D.* (1998) Importance of clinical activities to job satisfaction in Japanese pharmacists.  Am. J. Health-Syst. Pharm. 55, 360-363.

216.          Minami, T.*, Okazaki, J., Kawabata, A., Kawaki, H., Okazaki, Y. and Tohno, Y. (1998)  Roles of nitric oxide and prostaglandins in the increased permeability of the blood-brain barrier caused by lipopolysaccharide. Environ. Toxicol. Pharmacol. 5, 35-41.

217.          Kawabata, A.* and Hata, T. (1998) Disseminated intravascular coagulation (DIC)-like events produced by environmental stress and by lipopolysaccharide: Nitric oxide as a common key molecule.  In gThe Biology of Nitric Oxide Part 6h, edited by S. Moncada, N. Toda, H. Maeda and E.A. Higgs, pp.220, Portland Press (London) .

218.          Kawabata, A.* (1998) Brainstem – Endogenous analgesic substances and NO. Clinical Neuroscience 16, 775-777. (Review) (in Japanese)

 

Publications before 1998